Arguments for routine administration of probiotics for NEC prevention

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Probiotic administration to premature infants for the purpose of prevention of necrotizing enterocolitis is common in many parts of the world but uncommon in the United States. The present review will emphasize recent findings in support of routine administration of probiotics to this highly vulnerable population. RECENT FINDINGS: Additional evidence from animal models describing mechanisms of protection of probiotics in the immature gut and updated meta-analyses of randomized placebo-controlled trials and observational cohorts are presented (now including more than 40 000 premature infants from countries across the globe). SUMMARY: The preponderance of evidence suggests that probiotic administration to premature infants is well tolerated and decreases the risk of death, necrotizing enterocolitis, and sepsis. Further comparisons of probiotic administration to placebo are not likely to alter these conclusions. Rather, future work should focus on assurance of high-quality products with demonstrated purity and viability of probiotic microbes, and future clinical trials should focus on comparisons between high-quality products and doses.

Original languageEnglish (US)
Pages (from-to)188-194
Number of pages7
JournalCurrent opinion in pediatrics
Volume31
Issue number2
DOIs
StatePublished - Apr 1 2019

Fingerprint

Probiotics
Premature Infants
Necrotizing Enterocolitis
Placebos
Vulnerable Populations
Meta-Analysis
Sepsis
Randomized Controlled Trials
Animal Models
Clinical Trials

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Arguments for routine administration of probiotics for NEC prevention. / Underwood, Mark.

In: Current opinion in pediatrics, Vol. 31, No. 2, 01.04.2019, p. 188-194.

Research output: Contribution to journalArticle

@article{e1a9cc183e3b48ab963b89f049c33e49,
title = "Arguments for routine administration of probiotics for NEC prevention",
abstract = "PURPOSE OF REVIEW: Probiotic administration to premature infants for the purpose of prevention of necrotizing enterocolitis is common in many parts of the world but uncommon in the United States. The present review will emphasize recent findings in support of routine administration of probiotics to this highly vulnerable population. RECENT FINDINGS: Additional evidence from animal models describing mechanisms of protection of probiotics in the immature gut and updated meta-analyses of randomized placebo-controlled trials and observational cohorts are presented (now including more than 40 000 premature infants from countries across the globe). SUMMARY: The preponderance of evidence suggests that probiotic administration to premature infants is well tolerated and decreases the risk of death, necrotizing enterocolitis, and sepsis. Further comparisons of probiotic administration to placebo are not likely to alter these conclusions. Rather, future work should focus on assurance of high-quality products with demonstrated purity and viability of probiotic microbes, and future clinical trials should focus on comparisons between high-quality products and doses.",
author = "Mark Underwood",
year = "2019",
month = "4",
day = "1",
doi = "10.1097/MOP.0000000000000732",
language = "English (US)",
volume = "31",
pages = "188--194",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Arguments for routine administration of probiotics for NEC prevention

AU - Underwood, Mark

PY - 2019/4/1

Y1 - 2019/4/1

N2 - PURPOSE OF REVIEW: Probiotic administration to premature infants for the purpose of prevention of necrotizing enterocolitis is common in many parts of the world but uncommon in the United States. The present review will emphasize recent findings in support of routine administration of probiotics to this highly vulnerable population. RECENT FINDINGS: Additional evidence from animal models describing mechanisms of protection of probiotics in the immature gut and updated meta-analyses of randomized placebo-controlled trials and observational cohorts are presented (now including more than 40 000 premature infants from countries across the globe). SUMMARY: The preponderance of evidence suggests that probiotic administration to premature infants is well tolerated and decreases the risk of death, necrotizing enterocolitis, and sepsis. Further comparisons of probiotic administration to placebo are not likely to alter these conclusions. Rather, future work should focus on assurance of high-quality products with demonstrated purity and viability of probiotic microbes, and future clinical trials should focus on comparisons between high-quality products and doses.

AB - PURPOSE OF REVIEW: Probiotic administration to premature infants for the purpose of prevention of necrotizing enterocolitis is common in many parts of the world but uncommon in the United States. The present review will emphasize recent findings in support of routine administration of probiotics to this highly vulnerable population. RECENT FINDINGS: Additional evidence from animal models describing mechanisms of protection of probiotics in the immature gut and updated meta-analyses of randomized placebo-controlled trials and observational cohorts are presented (now including more than 40 000 premature infants from countries across the globe). SUMMARY: The preponderance of evidence suggests that probiotic administration to premature infants is well tolerated and decreases the risk of death, necrotizing enterocolitis, and sepsis. Further comparisons of probiotic administration to placebo are not likely to alter these conclusions. Rather, future work should focus on assurance of high-quality products with demonstrated purity and viability of probiotic microbes, and future clinical trials should focus on comparisons between high-quality products and doses.

UR - http://www.scopus.com/inward/record.url?scp=85062623627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062623627&partnerID=8YFLogxK

U2 - 10.1097/MOP.0000000000000732

DO - 10.1097/MOP.0000000000000732

M3 - Article

C2 - 30664022

AN - SCOPUS:85062623627

VL - 31

SP - 188

EP - 194

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 2

ER -